Human medicines European public assessment report (EPAR): Camcevi, leuprorelin, Date of authorisation: 24/05/2022, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Camcevi, leuprorelin, Date of authorisation: 24/05/2022, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): DuoPlavin, clopidogrel,acetylsalicylic acid, Date of authorisation: 14/03/2010, Revision: 32, Status: Authorised

Human medicines European public assessment report (EPAR): DuoPlavin, clopidogrel,acetylsalicylic acid, Date of authorisation: 14/03/2010, Revision: 32, Status: Authorised

Human medicines European public assessment report (EPAR): Enwylma, denosumab, Date of authorisation: 26/06/2025, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Enwylma, denosumab, Date of authorisation: 26/06/2025, Revision: 2, Status: Authorised

Committee for Medicinal Products for Human Use (CHMP): 14-17 September 2026, European Medicines Agency, Amsterdam, the Netherlands, from 14 September 2026 to 17 September 2026

Committee for Medicinal Products for Human Use (CHMP): 14-17 September 2026, European Medicines Agency, Amsterdam, the Netherlands, from 14 September 2026 to 17 September 2026

Human medicines European public assessment report (EPAR): Zonisamide Viatris (previously Zonisamide Mylan), zonisamide, Date of authorisation: 31/03/2016, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Zonisamide Viatris (previously Zonisamide Mylan), zonisamide, Date of authorisation: 31/03/2016, Revision: 14, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.